

Date: 13/08/2018



Vivimed

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.


The Board of Directors of the Company at its meeting held on August 13, 2018 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2018 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the quarter ended June 30, 2018.
3. Directors Report for the financial year ended 31.03.2018 together with annexure thereto.
4. Convening of Annual General Meeting (AGM) on 27.09.2018 and Notice of AGM.
5. Fixed Book closure dates from Saturday, September 22, 2018 to Thursday, September 27, 2018 (both days inclusive) for the purpose of AGM and Cut –off date/Record date for determining the names of the eligible Members for equity dividend is September 21, 2018.
6. Has accepted the resignation of Dr.Venkateswarulu Peesapati from the Board of Directors of the Company
7. The Board learnt about the sad demise of Sri.Venkata Ratnam Paluri, Director of the Company on July 01, 2018. The Board expressed its condolences and appreciated and put on record the valuable services rendered by Sri.Venkata Ratnam Paluri during his tenure of directorship in the Company.
8. Reconstituted various Committees of Board.

The dividend, if approved by the Members at the ensuing AGM, will be paid on or after October 1, 2018 and on or before October 26, 2018.

You are requested to take note of the above.

Yours faithfully
For VIVIMED LABS LIMITED


SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Limited (Registered Office)

CIN: L02411KA1988PLC009465

#78/A, Kolhar Industrial Area,

Bidar, Karnataka - 585 403, India.

T +91 (0) 8482-232045, F +91 (0) 8482-232436

Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

North End, Road No. 2

Banjara Hills, Hyderabad,

Telangana - 500 034, India.

T +91(0) 40-6608-6608, F +91(0) 40-6608-6699

VIVIMED LABS LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

Rs in Lakhs

Sl. No.	Particulars	Quarter Ended			YEAR ENDED
		30.06.2018 (Unaudited)	31.03.2018 (Audited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)
	Income From Operations				
1	Revenue from operations	35,854.14	28,560.95	31,797.42	1,18,178.83
	Total revenue from operations	35,854.14	28,560.95	31,797.42	1,18,178.83
2	Other Income	574.72	287.23	265.93	957.19
3	Total Revenue (1+2)	36,428.86	28,848.18	32,063.35	1,19,136.01
4	Expenses				
a	Cost of material consumed	15,025.35	13,204.27	12,204.51	48,980.29
b	Purchases of Stock- in- Trade				
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(742.70)	(2,339.01)	1,542.11	(1,012.92)
d	Employee Benefit Expenses	5,798.53	5,830.35	4,276.56	19,345.19
e	Finance Costs	1,928.00	1,636.63	2,422.98	7,923.83
f	Depreciation and Amortisation Expenses	1,586.73	1,383.95	1,255.60	5,641.96
8	Other Expenses	8,892.53	8,490.94	7,127.30	29,686.59
	Total Expenses	32,488.45	28,207.13	28,829.06	1,10,564.94
5	Profit before tax (3-4)	3,940.41	641.05	3,234.29	8,571.07
6	Tax expenses				
	Current Taxes	1,094.77	(18.73)	843.82	1,217.93
	Deferred Taxes	-	(231.27)	-	(255.81)
	Total tax expenses	1,094.77	(250.00)	843.82	962.12
7	Profit for the period /Year before non-controlling interest (5-6)	2,845.65	891.05	2,390.47	7,608.95
8	Non-controlling interest		185.29		
9	Profit for the period/ year (7-8)	2,845.65	1,076.34	2,390.47	7,608.95
10	Other comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax		(36.61)		(65.68)
	Items that will be reclassified to profit or loss, net of tax				
	Total other comprehensive income	-	(36.61)	-	(65.68)
11	Non-controlling interest	-	(36.61)	-	(65.68)
12	Other comprehensive income attributable to shareholders(10+11)	-	(36.61)	-	185.29
	Total comprehensive income attributable to:				
	Shareholders of the Company	2,845.65	1,039.73	2,390.47	7,728.55
	Non-controlling interest	-	(185.29)	-	-
	Total Comprehensive income	2,845.65	854.44	2,390.47	7,543.26
18	Paid up Equity Share Capital	1,650.48	1,650.48	1,639.73	1,620.38
19	Other equity				71,800.62
20	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)				
	(a) Basic	3.45	1.08	2.90	9.22
	(b) Diluted	3.41	1.07	2.86	9.11

1. The above Consolidated Unaudited Financial Results for the Quarter ended June 30.06.2018 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 13.08.2018

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma Pvt Limited (ii) Vivimed Speciality chemicals Pvt Ltd and its wholly owned foreign subsidiaries viz (i) Vivimed Labs USA, Inc., (ii) Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its stepdown subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimico Farmaceutica S.A.U., Spain, (viii) Holliday International Limited, UK & (ix) Uquifa Mexico S.A. de C.V. (x) Vivimed Labs (Mascarene) Ltd (xi) Soneas Chemicals Ltd (xii) Soneas Research Ltd and its Indian subsidiary (i) Vivimed life sciences Pvt Ltd

3. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 13.08.2018



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED				
SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED				
Particulars	3 Months Ended			Rs in Lakhs
	30.06.2018	31.03.2018	30.06.2017	FY 18
	(Unaudited)	(Audited)	(Unaudited)	31.03.2018
				(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	4,167.55	4,286.85	5,395.36	20,034.63
b.Pharma Business	31,686.59	24,274.10	26,402.06	98,531.39
Total	35,854.14	28,560.95	31,797.42	1,18,566.02
Less, Inter Segment Revenue				
Net sales / Income from Operations	35,854.14	28,560.95	31,797.42	1,18,566.02
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	1,365.21	764.12	1,526.74	6,223.17
b.Pharma Business	4,503.21	1,513.57	4,130.53	10,296.17
Total	5,868.42	2,277.69	5,657.27	16,519.34
Less: 1.Interest	1,928.00	1,636.63	2,422.98	7,948.27
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
Total Profit Before Tax	3,940.41	641.05	3,234.29	8,571.07
3. Capital Employed				
a.Speciality Chemicals Business	1,01,858.39	96,411.16	99,494.26	96,411.16
b.Pharma Business	1,07,382.39	1,02,444.56	65,503.29	1,02,444.56
	2,09,240.78	1,98,855.72	1,64,997.55	1,98,855.72
a.Segment Assets	2,58,511.78	2,39,362.76	2,07,252.29	2,39,362.76
b.Segment Liabilities	1,21,847.11	1,15,494.89	1,35,262.55	1,15,494.89
Place : Hyderabad Date : 13.08.2018  For VIVIMED LABS LIMITED (SANTOSH VARALWAR) MANAGING DIRECTOR				

VIVIMED LABS LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

Rs in Lakhs

Sl. No.	Particulars	3 Months Ended			Previous Year Ended 31.03.2018
		30.06.2018	31.03.2018	30.06.2017	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from Operations	6,198.53	6,799.06	6,635.60	26,138.59
	Total revenue from operations	6,198.53	6,799.06	6,635.60	26,138.59
2	Other Income	56.39	145.38	35.07	192.95
3	Total Revenue (1+2)	6,254.92	6,944.43	6,670.67	26,331.54
4	Expenses				
a	Cost of material consumed	2,998.98	3,198.05	2,552.72	11,494.73
b	Purchases of Stock-in- Trade	-	-	-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(975.91)	(1,207.40)	(119.08)	(2,854.63)
d	Employee Benefit Expenses	842.82	911.55	693.83	3,408.63
e	Finance Costs	1,138.70	1,385.55	1,214.95	5,180.22
f	Depreciation and Amortisation Expenses	482.89	400.08	447.07	1,814.36
8	Other Expenses	1,607.94	2,031.05	1,677.19	6,403.01
	Total Expenses	6,095.43	6,718.89	6,466.68	25,446.32
5	Profit before tax (3-4)	159.49	225.55	203.99	885.20
6	Tax Expenses				
	Current Taxes	31.90	44.03	40.80	170.25
	Deferred Taxes	-	(271.76)	-	(271.76)
	Total tax expenses	31.90	(227.73)	40.80	(101.51)
7	Profit for the period /Year (5-6)	127.59	453.28	163.19	986.71
8	Other Comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax	-	(36.29)	-	(65.37)
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-
	Total other comprehensive income	-	(36.29)	-	(65.37)
9	Total comprehensive income (7+8)	127.59	416.98	163.19	921.35
10	Paid up Equity Share Capital	1,650.48	1,650.48	1,639.73	1,650.48
11	Other equity				55,090.47
12	Earnings per Share (before Extraordinary Items) (of Rs2/- each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic	0.15	0.55	0.20	1.20
	(b) Diluted	0.15	0.54	0.20	1.18

1. The above Standalone Audited Financial Results for the Quarter & Year ended June 30, 2018 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 13.08.2018. The Financial results are prepared in accordance with the Indian Accounting standards (IndAS) as prescribed under section 133 of the companies Act, 2013 read with the companies (Indian Accounting Standards) Rules, 2015 (as amended)

2. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

3. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 13.08.2018



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED

Particulars	3 Months Ended			Rs in Lakhs
	30.06.2018	31.03.2018	30.06.2017	FY 18
	(Unaudited)	(Audited)	(Unaudited)	31.03.2018 (Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	1,769.29	2,077.62	1,660.95	7,161.20
b.Pharma Business	4,429.24	4,721.44	4,974.65	18,977.38
Total	6,198.53	6,799.06	6,635.60	26,138.58
Less, Inter Segment Revenue				
Net sales / Income from Operations	6,198.53	6,799.06	6,635.60	26,138.58
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	411.27	719.80	160.33	2,037.46
b.Pharma Business	886.92	891.30	1,258.61	4,027.96
Total	1,298.19	1,611.10	1,418.94	6,065.42
Less: 1.Interest	1,138.70	1,385.55	1,214.95	5,180.22
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
Total Profit Before Tax	159.49	225.55	203.99	885.20
3. Capital Employed				
a.Speciality Chemicals Business	74,267.21	71,873.81	77,330.89	71,873.81
b.Pharma Business	41,081.40	39,566.02	39,256.25	39,566.02
	1,15,348.61	1,11,439.83	1,16,587.14	1,11,439.83
4.				
a.Segment Assets	1,37,254.40	1,25,541.39	1,37,526.17	1,25,541.39
b. Segment Liabilities	74,985.60	68,800.44	82,412.35	68,800.44

Place : Hyderabad
Date : 13.08.2018



For VIVIMED LABS

(SANTOSH VARALWAR)
MANAGING DIRECTOR



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com


LIMITED REVIEW REPORT-CONSOLIDATED FINANCIAL RESULTS

To

The Board of Directors,
M/s. Vivimed Labs Limited,
Hyderabad

Limited Review Report for the quarter ended 30th June, 2018

1. We have reviewed the accompanying statement of unaudited Consolidated financial results ("the Statement") of M/s. Vivimed Labs Limited Group comprising M/s. Vivimed Labs Limited ("the Company") and its subsidiaries (together referred to as 'the group'), for the quarter ended 30th June, 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5th 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5th 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 13th August 2018. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide





P C N & ASSOCIATES

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates.,

Chartered Accountants.,

FRN: 016016S

Chandra Babu M

Partner

M.No. 227849



Place: Hyderabad

Date: 13th August 2018



P C N & ASSOCIATES

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

To

The Board of Directors
Vivimed Labs Limited
Hyderabad

Limited Review Report for the quarter ended 30th June, 2018

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. **Vivimed Labs Limited** for the quarter ended 30th June, 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 13th August, 2018. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 13th August 2018